Erythropoietin therapy

New England Journal of Medicine

Volumn 336, Issue 13, 1997, Pages 933-938

  Goodnough, Lawrence T ^a   Monk, Terri G ^a   Andriole, Gerald L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLEEDING; BLOOD AUTOTRANSFUSION; CANCER THERAPY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; ERYTHROPOIESIS; HEMATOCRIT; HEMODILUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; REVIEW; SURGICAL PATIENT;

ANEMIA; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; COST-BENEFIT ANALYSIS; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMODILUTION; HUMANS; POSTOPERATIVE COMPLICATIONS;

EID: 0030975564     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199703273361307     Document Type: Review

References (56)

1. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
2. Skolnick AA. As the blood supply gets safer, experts still call for ways to reduce the need for transfusions. JAMA 1992;268:698-700.
3. American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:403-6.
4. Joint Council of the American Red Cross, Council of Community Blood Centers, American Association of Blood Banks. Circular of Information for the Use of Human Blood Components. March 1994:6.
5. Eschbach JW, Egric JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoictin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
6. Goodnough LT, Anderson KC, Kurtz S, et al. Indications and guidelines for the use of hematopoietic growth factors. Transfusion 1993;33:944-59.
7. Krantz SB. Erythropoietin. Blood 1991;77:419-34.
8. Adamson JW, Spivak JL. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment. Surgery 1994;115:7-15.
9. Toy PTCY, Strauss RG, Stehling LC, et al. Predeposit autologous blood for elective surgery: a national multicenter study. N Engl J Med 1987;316: 517-20.
10. Goodnough LT, Shafron D, Marcus RE. Impact of preoperative autologous blood donation on orthopaedic surgical practice. Vox Sang 1990; 59:65-9.
11. Goodnough LT, Grishaber JE, Birkmeyer JD, Monk TG, Catalona WJ. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology 1994;44: 226-31.
12. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995;35:802-12.
13. The National Blood Resource Education Program Expert Panel. The use of autoiogous blood. JAMA 1990;263:414-7.
14. Renner SW, Howanitz PJ, Bachner P Preoperative autologous blood donation in 612 hospitals: a College of American Pathologists' Q-probes study of quality issues in transfusion practice. Arch Pathol Lab Med 1992; 116:613-9.
15. Toy PTCY, Menozzi D, Strauss RG, Stehling LC, Kruskall M, Ahn DK. Efficacy of preoperative donation of blood for autologous use in radical prostatectomy. Transfusion 1993;33:721-4.
16. Goodnough LT, Vizmeg K, Sobecks R, Schwarz A, Soegiarso W. Prevalence and classification of anemia in elective orthopaedic surgery patients: implications for blood conservation programs. Vox Sang 1992;63: 90-5.
17. Goodnough LT, Vizmeg K, Verbrugge D. The impact of autologous blood ordering and blood procurement practices on allogeneic blood exposure in elective orthopedic surgery patients. Am J Clin Pathol 1994;101: 354-7.
18. Goodnough LT, Brittenham GM. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990;115:28-35.
19. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988;260:65-7.
20. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163-8.
21. Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994;34:66-71.
22. Beris P, Mermillod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation: a prospective study. Vox Sang 1993;65:212-8.
23. Biesma DH, Marx JJ, Kraaljenhagen RJ, Franke W, Messinger D, van de Wiel A. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994;344:367-70.
24. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993;33:55-60.
25. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996;36:29-36.
26. Monk TG, Goodnough LT, Andriole GL, Colberg JW, Lemon DJ, Martin KJ. Preoperative recombinant human erythropoietin therapy enhances the efficacv of acute normovolemic hemodilution. Anesth Analg 1995;80:Suppl:S320. abstract.
27. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341:1227-32.
28. Paris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoictin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am 1996;78:62-72.
29. Goodnough LT, Monk TG, Brecher MF. Autologous blood procurement: lessons to be learned in the last 10 years. Vox Sang 1996;71:133-41.
30. Messmer K, Kreimeier U, Intaglietta M. Present state of intentional hemodilution. Eur Surg Res 1986;18:254-63.
31. Goodnough LT, Grishaber JE, Monk TG, Catalona WJ. Acute preoperative hemodilution in patients undergoing radical prostatectomy: a case study analysis of efficacy. Anesth Analg 1994;78:932-7.
32. Brecher ME, Rosenfeld M. Mathematical and computer modeling of acute normovolemic hemodilution. Transfusion 1994;34:176-9.
33. Goodnough LT, Bravo JR, Hsueh YS, Keating LJ, Brittenham GM. Red blood cell mass in autologous and homologous blood units: implications for risk/benefit assessment of autologous blood crossover and directed blood transfusion. Transfusion 1989;29:821-2.
34. Monk TG, Goodnough LT, Birkmeyer JD, Brecher ME, Catalona WJ. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion 1995;35:559-65.
35. Weiskopf RB. Mathematical analysis of isovolemic hemodilution indicates that it can decrease the need for allogeneic blood transfusion. Transfusion 1995;35:37-41.
36. Andriole GL, Smith DS, Rao G, Goodnough LT, Catalona WJ. Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol 1994;152:1858-60.
37. Winslow RM. Blood substitutes: current status. Transfusion 1989;29: 753-4.
38. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-24.
39. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993;33:544-51.
40. Sowadc O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with recombinant human erythropoietin (epoietin beta) in patients undergoing open-heart surgery. Blood 1997;89:411-8.
41. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995;126:57-6
42. 42. Goodnoughf LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32:441-5.
43. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation. J Am Coll Surg 1994;179:171-6.
44. Toy PTCY, Kaplan EB, McVay PA, Lee SJ, Strauss RG, Stehling LC. Blood Joss and replacement in total hip arthroplasty: a multicenter study. Transfusion 1992;32:63-7.
45. Goodnough LT, Vizmeg K, Marcus RE. Blood lost and transfused in patients undergoing elective orthopedic operation. Surg Gynecol Obstet 1993;176:235-8.
46. Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339-44.
47. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. Am J Med Qual 1994;9:172-83.
48. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2:1405-16.
49. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-22.
50. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996;25:544-52.
51. Powe NR, Griffiths RI, de Lissovoy G, et al. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 1992;268:1434-40.
52. Sisk JE, Gianfrancesco FD, Coster JM. Recombinant erythropoietin and Medicare payment. JAMA 1991;266:247-52.
53. Doolittle RF. Biotechnology - the enormous cost of success. N Engl J Med 1991;324:1360-2.
54. Cohen JA, Brecher ME. Preoperative autologous blood donation: benefit or detriment? A mathematical analysis. Transfusion 1995;35:640-4.
55. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:393-402.
56. Sans T, Bofil C, Joven J, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 1996;36: 822-6.